300204.SZ Stock Analysis
30
Uncovered
Staidson Beijing BioPharmaceuticals Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research and development, production, and marketing of innovative drugs with independent intellectual property rights. The company is headquartered in Beijing, Beijing and currently employs 873 full-time employees. The company went IPO on 2011-04-15. The Company’s products include mouse nerve growth factor for injection, which are applied in the neuroprotection and treatment of nerve injuries, as well as polyethylene glycol electrolyte powders, which are applied in the bowel cleansing and treatment of constipation. The firm mainly distributes its products in domestic market.